Loading clinical trials...

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke | Clinical Trials | Clareo Health

RECRUITINGNA

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT06045156•The First Hospital of Jilin University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT

Detailed Description

Nearly half of acute ischemic stroke patients underwent intravenous thrombolysis (IVT) failed to achieve excellent functional outcome. Some studies reported that early administrated tirofiban, a selective glycoproteinⅡb/Ⅲa receptor inhibitor, may greatly improve the outcome of patients who received IVT, however they only recruited small sample size. Thus, the investigators design early tirofiban administration after intravenous thrombolysis in acute ischemic stroke (ADVENT) trial, aiming to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age≥18 years old;
•2. Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
•3. Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
•4. Tirofiban or placebo treatment can be initiated within 6h after IVT;
•5. mRS score before onset≤ 1;
•6. Intracranial hemorrhage is ruled out by CT head after IVT;

Exclusion Criteria

•1. Received or plan to undergo bridge therapy;
•2. Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
•3. Atrial fibrillation or suspected cardiac embolism;
•4. Accompanied by epileptic seizures;
•5. Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;
•6. Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;
•7. Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year;
•8. Severe renal or liver insufficiency; ALT or AST\>3 times of the upper limit of normal value or above; creatinine clearance rate\<30 mL/min, creatinine\>200μmol/L；
•9. Life expectancy less than 3 months;
•10. Pregnant or lactating women;
+4 more criteria

Locations (1)

The first hospital of Jilin University

Changchun, Jilin, China

Key Dates

Start Date

April 29, 2024

Primary Completion Date

January 30, 2026

Completion Date

December 30, 2026

Last Updated

December 30, 2025

Enrollment

1,084

ESTIMATED participants

Conditions

Acute Ischemic Stroke

Interventions

Tirofiban

DRUG

Tirofiban simulant

DRUG

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

NCT07253181

Acute Ischemic StrokeLarge Vessel Occlusion+1 more

View study

RECRUITINGPHASE2/PHASE3

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867

Acute Ischemic Stroke

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Inclusion Criteria

Exclusion Criteria

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke

Brain, Blood And Clot or Tissue Registry And Collaboration

A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.

Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompressive Hemicraniectomy